162 related articles for article (PubMed ID: 37182335)
41. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.
Suzuki S; Kurabe N; Ohnishi I; Yasuda K; Aoshima Y; Naito M; Tanioka F; Sugimura H
Pathol Res Pract; 2015 May; 211(5):404-8. PubMed ID: 25466466
[TBL] [Abstract][Full Text] [Related]
42. Role of NSD1 as potential therapeutic target in tumor.
Yang C; Wang K; Liang Q; Tian TT; Zhong Z
Pharmacol Res; 2021 Nov; 173():105888. PubMed ID: 34536546
[TBL] [Abstract][Full Text] [Related]
43. Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3.
Turner-Ivey B; Smith EL; Rutkovsky AC; Spruill LS; Mills JN; Ethier SP
Breast Cancer Res Treat; 2017 Jul; 164(2):349-358. PubMed ID: 28484924
[TBL] [Abstract][Full Text] [Related]
44. Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4.
Zhang Q; Zeng L; Shen C; Ju Y; Konuma T; Zhao C; Vakoc CR; Zhou MM
Structure; 2016 Jul; 24(7):1201-8. PubMed ID: 27291650
[TBL] [Abstract][Full Text] [Related]
45. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes.
Taketani T; Taki T; Nakamura H; Taniwaki M; Masuda J; Hayashi Y
Cancer Genet Cytogenet; 2009 Apr; 190(2):108-12. PubMed ID: 19380029
[TBL] [Abstract][Full Text] [Related]
46. Inactivation of a histone methyltransferase by mutations in human cancers.
Kim KC; Geng L; Huang S
Cancer Res; 2003 Nov; 63(22):7619-23. PubMed ID: 14633678
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of NSD2 and NSD3 in overgrowth syndromes.
Douglas J; Coleman K; Tatton-Brown K; Hughes HE; Temple IK; Cole TR; Rahman N;
Eur J Hum Genet; 2005 Feb; 13(2):150-3. PubMed ID: 15483650
[TBL] [Abstract][Full Text] [Related]
48. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Pogribny IP; Ross SA; Tryndyak VP; Pogribna M; Poirier LA; Karpinets TV
Carcinogenesis; 2006 Jun; 27(6):1180-6. PubMed ID: 16497704
[TBL] [Abstract][Full Text] [Related]
49. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
50. Discovery of cysteine-targeting covalent histone methyltransferase inhibitors.
Zhao Y; Jiang B; Gu Z; Chen T; Yu W; Liu S; Liu X; Chen D; Li F; Chen W
Eur J Med Chem; 2023 Jan; 246():115028. PubMed ID: 36528996
[TBL] [Abstract][Full Text] [Related]
51. Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.
Milite C; Feoli A; Viviano M; Rescigno D; Mai A; Castellano S; Sbardella G
ChemMedChem; 2016 Aug; 11(16):1680-5. PubMed ID: 27411844
[TBL] [Abstract][Full Text] [Related]
52. Protein Lysine Methyltransferases Inhibitors.
Li Y; Ding L; Ren S; Zhang W; Rao GW
Curr Med Chem; 2023; 30(27):3060-3089. PubMed ID: 36043747
[TBL] [Abstract][Full Text] [Related]
53. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
[TBL] [Abstract][Full Text] [Related]
54. Non-histone Methylation of SET7/9 and its Biological Functions.
Gao L; Yu W; Song P; Li Q
Recent Pat Anticancer Drug Discov; 2022; 17(3):231-243. PubMed ID: 34856916
[TBL] [Abstract][Full Text] [Related]
55. Dissecting the Immunological Profiles in
Xu D; Liu S; Wu X; Marti TM; Dorn P; Schmid RA; Peng RW; Shu Y
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291782
[TBL] [Abstract][Full Text] [Related]
56. A Basic Post-SET Extension of NSDs Is Essential for Nucleosome Binding In Vitro.
Allali-Hassani A; Kuznetsova E; Hajian T; Wu H; Dombrovski L; Li Y; Gräslund S; Arrowsmith CH; Schapira M; Vedadi M
J Biomol Screen; 2014 Jul; 19(6):928-35. PubMed ID: 24595546
[TBL] [Abstract][Full Text] [Related]
57. Unsafe SETs: histone lysine methyltransferases and cancer.
Schneider R; Bannister AJ; Kouzarides T
Trends Biochem Sci; 2002 Aug; 27(8):396-402. PubMed ID: 12151224
[TBL] [Abstract][Full Text] [Related]
58. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
59. Interaction between DNA/histone methyltransferases and their inhibitors.
Hu J; Chen S; Kong X; Zhu K; Cheng S; Zheng M; Jiang H; Luo C
Curr Med Chem; 2015; 22(3):360-72. PubMed ID: 25386815
[TBL] [Abstract][Full Text] [Related]
60. Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Rubio-Tomás T
Mol Biol Rep; 2021 Nov; 48(11):7499-7508. PubMed ID: 34510321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
